Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take Mounjaro and want to give blood, the short answer is that you will need to pause donations while you are on treatment. NHS Blood and Transplant advises that donors on tirzepatide — the medicine in Mounjaro — should not give blood, primarily because the deferral period exists to protect both the donor and the recipient. This page explains exactly what that means in practice, what the NHS guidance says, and what to do if you were planning to donate.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
NHS Blood and Transplant maintains a list of medicines that trigger a donation deferral, and tirzepatide (the active ingredient in Mounjaro) sits on it. The deferral applies while you are taking the medicine. If you are wondering whether you can give blood if taking Mounjaro, the short answer is no, for as long as treatment continues.
The central reason for this rule is precautionary. Blood recipients can include people who are pregnant or trying to conceive, and tirzepatide is not recommended during pregnancy. Because it is impossible to guarantee how donated blood will be used, the safest approach is to prevent any exposure for a recipient who might be affected. It is the same logic applied to a number of other prescription medicines on the deferral list.
It is also worth noting that Mounjaro is a relatively new medicine, holding a Black Triangle (▼) designation from the MHRA, which flags that it is still subject to additional monitoring. Regulatory caution during this phase is standard practice. You can read more about tirzepatide's licensed use and monitoring status on the tirzepatide overview page.
Some people ask whether they could simply stop Mounjaro for a few weeks, donate, and then restart. That is a question for your prescriber, not one to answer yourself. Stopping and restarting a GLP-1 medicine mid-course can disrupt the titration schedule and may affect how your body tolerates the treatment when you return to it.
At nume, a named clinician reviews every repeat order before it is dispensed, so your prescriber already has visibility of your progress. If you are considering a temporary pause for donation purposes, raise it during your next review. There is no obligation to continue without a break if your circumstances change, but the timing and process matter, and getting that guidance is straightforward. You can find more general questions answered on the FAQs page.
The Mounjaro information page covers the full treatment picture, including how the dose schedule works, which is directly relevant if you are weighing a pause.
Donation criteria are maintained by NHS Blood and Transplant and can change. The definitive source for whether you can give blood on any given medicine (and for how long after stopping you must wait before donating) is their eligibility checker or helpline, not a third-party website including this one. Their criteria are reviewed as new evidence emerges, so checking at the point you are ready to donate is always the right move.
For context on how tirzepatide interacts with the body more broadly, the NHS medicines page for tirzepatide is a useful starting point; it summarises the medicine's profile in plain language. The NICE appraisal of tirzepatide (TA1026) provides the clinical evidence framework behind its licensed use in the UK.
If you have questions about what donating again might look like once treatment ends, NHS Blood and Transplant's team can advise on any waiting period that applies after your last dose. Related questions around donating on similar treatments are explored on this page about giving blood while taking Mounjaro.
For most people on Mounjaro, the blood donation question arises once and is then set aside until treatment ends. If you were a regular donor before starting, it is a genuine and thoughtful concern, and one our prescribers hear fairly often.
Treatment typically arrives as a KwikPen, tracked by DPD and delivered in plain packaging to your door. Life on treatment carries on largely as normal; the donation deferral is one of the few practical restrictions to be aware of alongside guidance on giving blood while on Mounjaro.
Driving, most forms of exercise, and routine medical appointments are unaffected. The deferral is not a blanket health restriction, it is a targeted precaution specific to blood donation. For anyone curious about the cost context of private treatment, the Mounjaro price page sets out what a private prescription typically involves.
If you have a specific concern about your treatment, speak to our prescribers. They review every consultation personally and can discuss your individual circumstances, including any plans around blood donation, without you needing to wait for a GP appointment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.